Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Myeloid 1Endocrine 1Dermatologic 1

Conditions

Uveal Melanoma 1Primary Myelofibrosis 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 72fludarabine phosphate 69Peripheral Blood Stem Cell Transplantation 58Mycophenolic Acid 56Whole-Body Irradiation 44Tacrolimus 44Cyclosporine 43Antilymphocyte Serum 39Busulfan 37Filgrastim 28Radiotherapy 27Methotrexate 26Cord Blood Stem Cell Transplantation 24Melphalan 20Methylprednisolone 19fludarabine 13Flow Cytometry 11Etoposide 11Sirolimus 10Therapeutics 9Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 7Cytarabine 7Cyclosporins 7Alemtuzumab 7thymoglobulin 6sargramostim 6Polymerase Chain Reaction 6Rituximab 5Allopurinol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × avelumab × Myeloid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡